Harrow, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
Harrow, Inc. (HROW) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $48.18 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2026-03-02
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2025-03-31 was $45.64, a 76.49% increase year-over-year.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2024-03-31 was $25.86, a 40.93% increase year-over-year.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2023-03-31 was $18.35, a 104.12% increase year-over-year.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for the quarter ending 2022-03-31 was $8.99, a 0.00% change year-over-year.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2025 was $48.18, a 5.57% increase from fiscal 2024.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2024 was $45.64, a 76.49% increase from fiscal 2023.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2023 was $25.86, a 108.89% increase from fiscal 2022.
- Harrow, Inc. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2022 was $12.38.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 3 month | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 6 month | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 9 month | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $48.18 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $48.18 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $45.64 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $45.64 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $45.64 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $39.63 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $25.86 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $25.86 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $25.86 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $25.86 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $25.86 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $18.35 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $12.38 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $8.99 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $8.99 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $8.99 10-Q · filed 2022-05-05 | |||
| 2021-09-30 | $8.99 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $8.99 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $8.99 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $8.99 10-K · filed 2022-03-10 | |||
| 2020-09-30 | $8.99 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $42.80 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $42.80 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $42.80 10-K · filed 2020-03-13 | |||
| 2019-09-30 | $42.80 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $42.80 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $42.80 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $42.80 10-K · filed 2019-03-12 | |||
| 2018-09-30 | $42.80 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $42.80 10-Q · filed 2018-08-06 | |||
| 2018-03-31 | $42.80 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $42.80 10-K · filed 2018-03-08 | |||
| 2017-09-30 | $42.80 10-Q · filed 2017-11-14 | |||
| 2017-06-30 | $42.80 10-Q · filed 2017-08-10 | |||
| 2017-03-31 | $42.80 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |